US20030031708A1 - Synergistic filler composition - Google Patents
Synergistic filler composition Download PDFInfo
- Publication number
- US20030031708A1 US20030031708A1 US09/915,057 US91505701A US2003031708A1 US 20030031708 A1 US20030031708 A1 US 20030031708A1 US 91505701 A US91505701 A US 91505701A US 2003031708 A1 US2003031708 A1 US 2003031708A1
- Authority
- US
- United States
- Prior art keywords
- tablet
- composition
- microcrystalline cellulose
- copolymer
- pvp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Seeds, Soups, And Other Foods (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
- 1. Field of the Invention
- This invention relates to pharmaceutical tableting, and, more particularly, to a synergistic filler composition which provides increased tablet hardness and low friability at low compression forces without increasing the size of the tablet.
- 2. Description of the Prior Art
- Many commercial filler materials are used including microcrystalline cellulose and silicified microcrystalline cellulose inn the manufacture of pharmaceutical tablets. Such materials are described in the paper by Tobyn, M. J. in Int. J. of Pharmaceutics, 169, 183-194 (1998). However drugs which are difficult to compress require tableting machines which can operate at high compression forces in order to provide suitable hardness and low friability properties. Also, large amounts of the filler may be necessary to achieve these results, which, disadvantageously, increases the size of the tablet.
- Accordingly, it is an object of this invention to provide a drug tableting filler composition of two components which act synergistically with respect to increasing hardness and decreasing friability for pharmaceutical tablets at a given compression force, and without increasing the size of the tablet.
- This and other objects and features of the invention will be made apparent from the following description of the invention
- FIG. 1 is a plot of tablet hardness (KP) vs. concentration (wt. %) of PVP-VA copolymer in a composition with silicified microcrystalline cellulose (silicified MCC/ProSolv®) at a given compression force.
- FIG. 2 is a similar plot for mixtures of copolymer and microcrystalline cellulose (MCC102).
- FIG. 3 is a similar plot for a drug tablet of 67 wt. % acetaminophen (APAP) and silicified microcrystalline cellulose, with and without PVP/VA copolymer.
- FIG. 4 is a similar plot as FIG. 3 for a composition containing microcrystalline cellulose.
- FIG. 5 is a similar plot of 60% aspirin and silicified microcellulose with and without PVP/VA copolymer.
- FIG. 6 is a similar plot of a drug tablet with 60 wt. % aspirin and a mix of microcrystalline cellulose (MCC 102) with and without PVP/VA copolymer.
- FIG. 7 is a similar plot as FIG. 6 of a drug tablet with 67 wt. % diltiazem HCl as the model drug.
- What is described herein is a synergistic filler composition for making pharmaceutical tablets of increased tablet hardness and low friability without substantially increasing the size of the tablet, comprising (a) a PVP-VA copolymer and (b) microcrystalline cellulose.
- Preferred compositions are those wherein (b) is a silicified microcrystalline cellulose; and (a) is present in an amount of about 5-30%; most preferably 10-20%.
- Other preferred compositions are those wherein (a) comprises, by weight, 80-60% PVP and 20-40% VA.
- In this invention, there is provided synergistic filler compositions of (a) vinyl pyrrolidone-vinyl acetate copolymers, and (b) microcrystalline cellulose, preferably silicified microcrystalline cellulose, which provide a synergistic increase in hardness, and a synergistic decrease in friability, for tableted drugs containing such fillers. These results are achieved herein with only a minimum amount of the filler composition, and without increasing the size of the tablet.
- The invention will be further described by reference to the experimental results illustrated in the drawings.
- Accordingly, FIGS. 1 and 2 shows a plot of tablet hardness (KP) vs. concentration (wt. %) of PVP-VA copolymer in a composition with microcrystalline cellulose at a given compression force of 2000, 4000 and 6000 lbs. As shown in FIGS. 1 and 2, the composition of the invention provides a synergistic increase in tablet compressibility (hardness) with an increase in the concentration of PVP-VA copolymer in the composition up to about 30 wt. % of PVP/VA copolymer, as evidenced by the convex shape of the curve. The maximum synergistic effect is obtained at about 20 wt. % PVP-VA copolymer. Further increases in copolymer produces only marginal improvement in tablet hardness.
- These results contrast with the individual components alone, or PVP-VA copolymer with other known fillers, such as lactose or dicalcium phosphate, where the hardness increase is observed to be only linear with increasing copolymer concentration.
- The microcrystalline cellulose component of the composition is available commercially as ProSolv® (silicified microcrystalline cellulose) and as MCC 102 (microcrystalline cellulose).
- The advantageous results demonstrated herein for the composition of the invention were obtained similarly for drugs which are difficult to compress into small tablets without using an excessive amount of filler/binder. Such large amounts of filler/binder would preclude formulation of the drug into tablets of high dosage.
- Referring now to FIGS. 3 and 4, there is shown the manufacture of drug-containing tablets with the composition of the invention using acetaminophen as a model drug.
COMPOSITIONS OF DRUG TABLETS (WT. %) FIGS. 3-4 67 APAP 30 Copolymer (25 cellulose + 5 PVP/VA) 2 PVPP (XL) 0.5 SiO2 (colloid) 0.5 Mg stearate 100 FIGS. 5-6 60 Aspirin 37 Copolymer (27 + 10) 2 PVPP (XL) 0.5 SiO2 0.5 Mg stearate 100 FIG. 7 65 Diltiazem HCI 32 Copolymer (22 + 10) 2 PVPP (XL) 0.5 SiO2 0.5 Mg stearate 100 - Similar synergistic effects were obtained for aspirin tablets containing (FIGS. 5 and 6) and for diltiazem HCl (FIG. 7) as model drugs.
- In summary, the invention composition herein provides a synergistic action in drug tableting formulations of even difficult to compress drugs. The observed hardness is sufficient to prevent damage to the tablet upon further processing of the tablet, including coating and packaging. The tablet hardness obtained herein is preferably at least 3 KP, and its friability is <0.7%, usually <0.5%. Both properties are indicative of a new and improved composition in the field of drug tableting.
- While the invention has been described with particular reference to certain embodiments thereof, it will be understood that changes and modifications may be made which are within the skill of the art. Accordingly, it is intended to be bound only by the following claims, in which:
Claims (8)
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/915,057 US6524617B1 (en) | 2001-07-25 | 2001-07-25 | Synergistic filler composition |
PCT/US2002/014586 WO2003011253A1 (en) | 2001-07-25 | 2002-05-10 | Synergistic filler composition |
CA2454449A CA2454449C (en) | 2001-07-25 | 2002-05-10 | Synergistic filler composition of pvp-va and silicified mycrocrystalline cellulose for tablet dosage form |
MXPA04000666A MXPA04000666A (en) | 2001-07-25 | 2002-05-10 | Synergistic filler composition. |
AT02734286T ATE327738T1 (en) | 2001-07-25 | 2002-05-10 | SYNERGISTIC FILLING COMPOSITION |
ES02734286T ES2266502T3 (en) | 2001-07-25 | 2002-05-10 | SYNTHETIC FILLING COMPOSITION. |
EP02734286A EP1416918B1 (en) | 2001-07-25 | 2002-05-10 | Synergistic filler composition |
DE60211916T DE60211916T2 (en) | 2001-07-25 | 2002-05-10 | SYNERGISTIC FILLING COMPOSITION |
CNB028185161A CN1268320C (en) | 2001-07-25 | 2002-05-10 | Synergistic filler composition |
BRPI0211439-9A BRPI0211439B1 (en) | 2001-07-25 | 2002-05-10 | COMPOSITION OF SYNERGISTIC CHARGE AND PHARMACEUTICAL TABLET |
RU2004105268/15A RU2304981C2 (en) | 2001-07-25 | 2002-05-10 | Synergetic filling agent composition |
JP2003516485A JP4805537B2 (en) | 2001-07-25 | 2002-05-10 | Synergistic excipient composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/915,057 US6524617B1 (en) | 2001-07-25 | 2001-07-25 | Synergistic filler composition |
Publications (2)
Publication Number | Publication Date |
---|---|
US20030031708A1 true US20030031708A1 (en) | 2003-02-13 |
US6524617B1 US6524617B1 (en) | 2003-02-25 |
Family
ID=25435143
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/915,057 Expired - Lifetime US6524617B1 (en) | 2001-07-25 | 2001-07-25 | Synergistic filler composition |
Country Status (12)
Country | Link |
---|---|
US (1) | US6524617B1 (en) |
EP (1) | EP1416918B1 (en) |
JP (1) | JP4805537B2 (en) |
CN (1) | CN1268320C (en) |
AT (1) | ATE327738T1 (en) |
BR (1) | BRPI0211439B1 (en) |
CA (1) | CA2454449C (en) |
DE (1) | DE60211916T2 (en) |
ES (1) | ES2266502T3 (en) |
MX (1) | MXPA04000666A (en) |
RU (1) | RU2304981C2 (en) |
WO (1) | WO2003011253A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070036859A1 (en) * | 2005-08-11 | 2007-02-15 | Perry Ronald L | Sustained release antihistamine and decongestant composition |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6620900B2 (en) * | 2002-02-07 | 2003-09-16 | Isp Investments Inc. | Proliferous copolymer of vinyl pyrrolidone and vinyl acetate |
JP4776233B2 (en) * | 2002-11-12 | 2011-09-21 | エラン ファーマ インターナショナル,リミティド | Fast disintegrating solid formulation that is resistant to abrasion and contains pullulan |
US7704528B2 (en) * | 2003-05-05 | 2010-04-27 | Isp Investments Inc. | Binder composition and method for processing poorly compressible drugs into tablets of predetermined hardness and friability |
US8168219B2 (en) * | 2005-11-30 | 2012-05-01 | Isp Investments Inc. | Synergistic binder composition, method for making same, and tablets of an active and said binder having advantageous hardness and friability |
ES2738182T3 (en) * | 2013-03-12 | 2020-01-20 | Hercules Llc | Polypropylene Coated Silica Coated Composition |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU183408B (en) * | 1981-04-28 | 1984-05-28 | Chinoin Gyogyszer Es Vegyeszet | Process for producing oral ratard pharmaceutical compositions |
US5326570A (en) * | 1991-07-23 | 1994-07-05 | Pharmavene, Inc. | Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine |
DE69617245T2 (en) * | 1995-08-17 | 2002-07-25 | Csir Pretoria | CONTROLLED RELEASE PRODUCTS |
AT413647B (en) * | 1998-11-26 | 2006-04-15 | Sandoz Ag | USE OF A COPOLYMERISATE OF 1-VINYL-2-PYRROLIDONE AND VINYL ACETATE FOR THE PREPARATION OF CEFUROXIMAXETIL-SUBJECTED TABLETS |
-
2001
- 2001-07-25 US US09/915,057 patent/US6524617B1/en not_active Expired - Lifetime
-
2002
- 2002-05-10 DE DE60211916T patent/DE60211916T2/en not_active Expired - Lifetime
- 2002-05-10 RU RU2004105268/15A patent/RU2304981C2/en active
- 2002-05-10 CN CNB028185161A patent/CN1268320C/en not_active Expired - Lifetime
- 2002-05-10 JP JP2003516485A patent/JP4805537B2/en not_active Expired - Lifetime
- 2002-05-10 ES ES02734286T patent/ES2266502T3/en not_active Expired - Lifetime
- 2002-05-10 BR BRPI0211439-9A patent/BRPI0211439B1/en not_active IP Right Cessation
- 2002-05-10 EP EP02734286A patent/EP1416918B1/en not_active Expired - Lifetime
- 2002-05-10 CA CA2454449A patent/CA2454449C/en not_active Expired - Lifetime
- 2002-05-10 WO PCT/US2002/014586 patent/WO2003011253A1/en active IP Right Grant
- 2002-05-10 MX MXPA04000666A patent/MXPA04000666A/en active IP Right Grant
- 2002-05-10 AT AT02734286T patent/ATE327738T1/en not_active IP Right Cessation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070036859A1 (en) * | 2005-08-11 | 2007-02-15 | Perry Ronald L | Sustained release antihistamine and decongestant composition |
Also Published As
Publication number | Publication date |
---|---|
BR0211439A (en) | 2004-07-20 |
CA2454449A1 (en) | 2003-02-13 |
CN1556695A (en) | 2004-12-22 |
WO2003011253A1 (en) | 2003-02-13 |
DE60211916T2 (en) | 2007-01-04 |
BRPI0211439B1 (en) | 2017-09-19 |
EP1416918A4 (en) | 2004-08-18 |
DE60211916D1 (en) | 2006-07-06 |
US6524617B1 (en) | 2003-02-25 |
BRPI0211439B8 (en) | 2021-05-25 |
ATE327738T1 (en) | 2006-06-15 |
RU2304981C2 (en) | 2007-08-27 |
MXPA04000666A (en) | 2004-04-05 |
EP1416918B1 (en) | 2006-05-31 |
RU2004105268A (en) | 2005-03-10 |
EP1416918A1 (en) | 2004-05-12 |
CA2454449C (en) | 2010-10-26 |
JP2005501049A (en) | 2005-01-13 |
JP4805537B2 (en) | 2011-11-02 |
ES2266502T3 (en) | 2007-03-01 |
CN1268320C (en) | 2006-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1274401B2 (en) | Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids | |
CA2463583A1 (en) | Highly compressible ethylcellulose for tableting | |
JP2009507047A5 (en) | ||
EP1321142A1 (en) | Solid pharmaceutical composition for oral administration of Tegaserod | |
EP0454396A1 (en) | Tablet composition and method for problem pharmaceutical materials | |
EP2983719A1 (en) | Manufacturing process for effervescent dosage forms | |
US6524617B1 (en) | Synergistic filler composition | |
CA2423574A1 (en) | Stabilization of solid drug formulations | |
JP2009513530A5 (en) | ||
AU2002348279C1 (en) | Soluble drug extended release system | |
WO2007016350A2 (en) | Modified release tablet formulations with enhanced mechanical properties | |
US7897172B2 (en) | Tablets exhibiting reduced drug release variability | |
US8168219B2 (en) | Synergistic binder composition, method for making same, and tablets of an active and said binder having advantageous hardness and friability | |
US6737419B2 (en) | Benazepril hydrochloride tablet formulations | |
US20050271718A1 (en) | Sustained release propafenone hydrochloride capsules | |
CA2217238A1 (en) | Cross-linked cellulose as a tablet excipient | |
US20040131672A1 (en) | Direct compression pharmaceutical composition containing a pharmaceutically active ingredient with poor flowing properties | |
WO2008001184A2 (en) | Solid composition | |
WO2002045753A3 (en) | Oral extended release formulation of gepirone | |
AU2005201185B2 (en) | Stable pharmaceutical compositions containing 7-substituted-3, 5-dihydroxyheptanoic acids or 7-substituted-3, 5-dihydroxyheptenoic acids | |
Schwartz et al. | Influence of lubricants on the tableting and disintegration time of tablets made up of coprecessed excipients vs. the physical blends | |
Dressler et al. | A Corn Starch/a-Lactose Monohydrate Compound as a Directly Compressible Excipient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ISP INVESTMENTS INC., DELAWARE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MORONI, ANTONIO;NERELLA, NADHAMUNI G.;BROWNY, GREGORY DU;REEL/FRAME:012049/0506;SIGNING DATES FROM 20010719 TO 20010723 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
AS | Assignment |
Owner name: THE BANK OF NOVA SCOTIA, AS ADMINISTRATIVE AGENT, Free format text: SECURITY AGREEMENT;ASSIGNORS:ASHLAND LICENSING AND INTELLECTUAL PROPERTY LLC;HERCULES INCORPORATED;AQUALON COMPANY;AND OTHERS;REEL/FRAME:026918/0052 Effective date: 20110823 |
|
AS | Assignment |
Owner name: VERONA, INC., NEW JERSEY Free format text: PATENT RELEASE;ASSIGNOR:JPMORGAN CHASE BANK, N.A. (F/K/A THE CHASE MANHATTAN BANK);REEL/FRAME:026930/0774 Effective date: 20110823 Owner name: ISP CAPITAL, INC., NEW JERSEY Free format text: PATENT RELEASE;ASSIGNOR:JPMORGAN CHASE BANK, N.A. (F/K/A THE CHASE MANHATTAN BANK);REEL/FRAME:026930/0774 Effective date: 20110823 Owner name: ISP CHEMICAL PRODUCTS, INC., NEW JERSEY Free format text: PATENT RELEASE;ASSIGNOR:JPMORGAN CHASE BANK, N.A. (F/K/A THE CHASE MANHATTAN BANK);REEL/FRAME:026930/0774 Effective date: 20110823 |
|
AS | Assignment |
Owner name: ASHLAND LICENSING AND INTELLECTUAL PROPERTY LLC, OHIO Free format text: RELEASE OF PATENT SECURITY AGREEMENT;ASSIGNOR:THE BANK OF NOVA SCOTIA;REEL/FRAME:030025/0320 Effective date: 20130314 Owner name: AQUALON COMPANY, DELAWARE Free format text: RELEASE OF PATENT SECURITY AGREEMENT;ASSIGNOR:THE BANK OF NOVA SCOTIA;REEL/FRAME:030025/0320 Effective date: 20130314 Owner name: ISP INVESTMENTS INC., DELAWARE Free format text: RELEASE OF PATENT SECURITY AGREEMENT;ASSIGNOR:THE BANK OF NOVA SCOTIA;REEL/FRAME:030025/0320 Effective date: 20130314 Owner name: HERCULES INCORPORATED, DELAWARE Free format text: RELEASE OF PATENT SECURITY AGREEMENT;ASSIGNOR:THE BANK OF NOVA SCOTIA;REEL/FRAME:030025/0320 Effective date: 20130314 Owner name: ASHLAND LICENSING AND INTELLECTUAL PROPERTY LLC, O Free format text: RELEASE OF PATENT SECURITY AGREEMENT;ASSIGNOR:THE BANK OF NOVA SCOTIA;REEL/FRAME:030025/0320 Effective date: 20130314 |
|
FPAY | Fee payment |
Year of fee payment: 12 |
|
AS | Assignment |
Owner name: ISP INVESTMENTS LLC, DELAWARE Free format text: CONVERSION;ASSIGNOR:ISP INVESTMENTS INC.;REEL/FRAME:041556/0499 Effective date: 20160818 |
|
AS | Assignment |
Owner name: THE BANK OF NOVA SCOTIA, AS ADMINISTRATIVE AGENT, CANADA Free format text: SECURITY AGREEMENT;ASSIGNORS:AVOCA, INC.;HERCULES LLC;ISP INVESTMENTS LLC;AND OTHERS;REEL/FRAME:043084/0753 Effective date: 20170630 Owner name: THE BANK OF NOVA SCOTIA, AS ADMINISTRATIVE AGENT, Free format text: SECURITY AGREEMENT;ASSIGNORS:AVOCA, INC.;HERCULES LLC;ISP INVESTMENTS LLC;AND OTHERS;REEL/FRAME:043084/0753 Effective date: 20170630 |
|
AS | Assignment |
Owner name: HERCULES LLC, DELAWARE Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:THE BANK OF NOVA SCOTIA;REEL/FRAME:051557/0504 Effective date: 20200110 Owner name: AVOCA LLC, NORTH CAROLINA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:THE BANK OF NOVA SCOTIA;REEL/FRAME:051557/0504 Effective date: 20200110 Owner name: PHARMACHEM LABORATORIES LLC, NEW JERSEY Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:THE BANK OF NOVA SCOTIA;REEL/FRAME:051557/0504 Effective date: 20200110 Owner name: ISP INVESTMENTS LLC, NEW JERSEY Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:THE BANK OF NOVA SCOTIA;REEL/FRAME:051557/0504 Effective date: 20200110 |